circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Q3 2019 Cytokinetics, Inc. Earnings Conference Call
    Oct 31, 2019 4:30 PM EDT

    Q3 2019 Cytokinetics, Inc. Earnings Conference Call
    Oct 31, 2019 4:30 PM EDT
  • Webcast
    X Cantor Fitzgerald Global Healthcare Conference
    Oct 3, 2019 10:40 AM EDT

    Cantor Fitzgerald Global Healthcare Conference
    Oct 3, 2019 10:40 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019
SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv
Toggle Summary Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has agreed to sell an aggregate of $120.0 million principal amount of its 4.00% convertible senior notes due 2026, or the notes, in an underwritten public offering.
Toggle Summary Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it expects to sell, subject to market and other conditions, an aggregate of $100.0 million principal amount of its convertible senior notes due 2026, or the notes, in an
Toggle Summary Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is scheduled to participate in the Credit Suisse 28 th Annual Healthcare Conference on

EVENTS

There are currently no events to display.